146 related articles for article (PubMed ID: 18084958)
1. Immunotherapeutic approaches in pancreatic cancer.
Stieler J
Recent Results Cancer Res; 2008; 177():165-77. PubMed ID: 18084958
[TBL] [Abstract][Full Text] [Related]
2. Pancreatic cancer immunotherapy using a tumor lysate vaccine, engineered to express α-gal epitopes, targets pancreatic cancer stem cells.
Tanida T; Tanemura M; Miyoshi E; Nagano H; Furukawa K; Nonaka Y; Akita H; Hama N; Wada H; Kawamoto K; Kobayashi S; Eguchi H; Mori M; Doki Y
Int J Oncol; 2015 Jan; 46(1):78-90. PubMed ID: 25354268
[TBL] [Abstract][Full Text] [Related]
3. Pancreatic cancer: role of the immune system in cancer progression and vaccine-based immunotherapy.
Amedei A; Niccolai E; Prisco D
Hum Vaccin Immunother; 2014; 10(11):3354-68. PubMed ID: 25483688
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapeutic Approaches in Pancreatic Adenocarcinoma: Current Status and Future Perspectives.
Yee NS
Curr Mol Pharmacol; 2016; 9(3):231-241. PubMed ID: 26177643
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy synergizes with chemotherapy targeting pancreatic cancer.
Koido S; Homma S; Takahara A; Namiki Y; Komita H; Uchiyama K; Ito M; Gong J; Ohkusa T; Tajiri H
Immunotherapy; 2012 Jan; 4(1):5-7. PubMed ID: 22149993
[No Abstract] [Full Text] [Related]
6. Current immunotherapeutic strategies in pancreatic cancer.
Plate JM
Surg Oncol Clin N Am; 2007 Oct; 16(4):919-43, xi. PubMed ID: 18022552
[TBL] [Abstract][Full Text] [Related]
7. Emerging trends in the immunotherapy of pancreatic cancer.
Banerjee K; Kumar S; Ross KA; Gautam S; Poelaert B; Nasser MW; Aithal A; Bhatia R; Wannemuehler MJ; Narasimhan B; Solheim JC; Batra SK; Jain M
Cancer Lett; 2018 Mar; 417():35-46. PubMed ID: 29242097
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity of recombinant GA733-2E antigen (CO17-1A, EGP, KS1-4, KSA, Ep-CAM) in gastro-intestinal carcinoma patients.
Staib L; Birebent B; Somasundaram R; Purev E; Braumüller H; Leeser C; Küttner N; Li W; Zhu D; Diao J; Wunner W; Speicher D; Beger HG; Song H; Herlyn D
Int J Cancer; 2001 Apr; 92(1):79-87. PubMed ID: 11279610
[TBL] [Abstract][Full Text] [Related]
9. A New Approach for Cancer Immunotherapy Based on the Cancer Stem Cell Antigens Properties.
Mahmoodi S; Nezafat N; Negahdaripour M; Ghasemi Y
Curr Mol Med; 2019; 19(1):2-11. PubMed ID: 30714514
[TBL] [Abstract][Full Text] [Related]
10. In vivo induction of dendritic cell-mediated cytotoxicity against allogeneic pancreatic carcinoma cells.
Stift A; Friedl J; Dubsky P; Bachleitner-Hofmann T; Benkoe T; Brostjan C; Jakesz R; Gnant M
Int J Oncol; 2003 Mar; 22(3):651-6. PubMed ID: 12579320
[TBL] [Abstract][Full Text] [Related]
11. Q&A: Evidence presenter. Interview by Marian Turner.
Palucka K
Nature; 2013 Dec; 504(7480):S9. PubMed ID: 24352364
[No Abstract] [Full Text] [Related]
12. Lysates of S. pyogenes serotype M49 induce pancreatic tumor growth delay by specific and unspecific antitumor immune responses.
Linnebacher M; Maletzki C; Emmrich J; Kreikemeyer B
J Immunother; 2008 Oct; 31(8):704-13. PubMed ID: 18779749
[TBL] [Abstract][Full Text] [Related]
13. Current immunotherapeutic approaches in pancreatic cancer.
Koido S; Homma S; Takahara A; Namiki Y; Tsukinaga S; Mitobe J; Odahara S; Yukawa T; Matsudaira H; Nagatsuma K; Uchiyama K; Satoh K; Ito M; Komita H; Arakawa H; Ohkusa T; Gong J; Tajiri H
Clin Dev Immunol; 2011; 2011():267539. PubMed ID: 21922022
[TBL] [Abstract][Full Text] [Related]
14. Immunologic approaches to the management of pancreatic cancer.
Laheru D; Biedrzycki B; Jaffee EM
Cancer J; 2001; 7(4):324-37. PubMed ID: 11561608
[TBL] [Abstract][Full Text] [Related]
15. Immunoprevention of Pancreatic Cancer.
Rao CV; Mohammed A; Asch AS; Janakiram NB
Curr Med Chem; 2018; 25(22):2576-2584. PubMed ID: 28240168
[TBL] [Abstract][Full Text] [Related]
16. Increased immunogenicity of tumor-associated antigen, mucin 1, engineered to express alpha-gal epitopes: a novel approach to immunotherapy in pancreatic cancer.
Deguchi T; Tanemura M; Miyoshi E; Nagano H; Machida T; Ohmura Y; Kobayashi S; Marubashi S; Eguchi H; Takeda Y; Ito T; Mori M; Doki Y; Sawa Y
Cancer Res; 2010 Jul; 70(13):5259-69. PubMed ID: 20530670
[TBL] [Abstract][Full Text] [Related]
17. Potential targets for pancreatic cancer immunotherapeutics.
Dodson LF; Hawkins WG; Goedegebuure P
Immunotherapy; 2011 Apr; 3(4):517-37. PubMed ID: 21463193
[TBL] [Abstract][Full Text] [Related]
18. [Identification of cancer-stem cell antigens and development of CTL-mediated cancer immunotherapy].
Miyamoto S; Kanaseki T; Hirohashi Y; Tsukahara T; Kikuchi Y; Sato N; Torigoe T
Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(1):40-47. PubMed ID: 28539553
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy for pancreatic cancer - science driving clinical progress.
Laheru D; Jaffee EM
Nat Rev Cancer; 2005 Jun; 5(6):459-67. PubMed ID: 15905855
[TBL] [Abstract][Full Text] [Related]
20. New targeted therapies in pancreatic cancer.
Seicean A; Petrusel L; Seicean R
World J Gastroenterol; 2015 May; 21(20):6127-45. PubMed ID: 26034349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
